- Home
- SNGX vs FOXO Comparison
SNGX vs FOXO Comparison
Compare SNGX & FOXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- FOXO
- Stock Information
- Founded
- SNGX 1987
- FOXO 2019
- Country
- SNGX United States
- FOXO United States
- Employees
- SNGX N/A
- FOXO N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- FOXO Retail: Computer Software & Peripheral Equipment
- Sector
- SNGX Health Care
- FOXO Technology
- Exchange
- SNGX Nasdaq
- FOXO Nasdaq
- Market Cap
- SNGX 9.6M
- FOXO 8.0M
- IPO Year
- SNGX 1987
- FOXO N/A
- Fundamental
- Price
- SNGX $3.16
- FOXO $0.32
- Analyst Decision
- SNGX
- FOXO
- Analyst Count
- SNGX 0
- FOXO 0
- Target Price
- SNGX N/A
- FOXO N/A
- AVG Volume (30 Days)
- SNGX 46.1K
- FOXO 9.1M
- Earning Date
- SNGX 11-08-2024
- FOXO 11-19-2024
- Dividend Yield
- SNGX N/A
- FOXO N/A
- EPS Growth
- SNGX N/A
- FOXO N/A
- EPS
- SNGX N/A
- FOXO N/A
- Revenue
- SNGX $364,183.00
- FOXO $1,341,000.00
- Revenue This Year
- SNGX N/A
- FOXO N/A
- Revenue Next Year
- SNGX $76.64
- FOXO N/A
- P/E Ratio
- SNGX N/A
- FOXO N/A
- Revenue Growth
- SNGX N/A
- FOXO 196.03
- 52 Week Low
- SNGX $1.83
- FOXO $0.13
- 52 Week High
- SNGX $19.20
- FOXO $1.30
- Technical
- Relative Strength Index (RSI)
- SNGX 41.70
- FOXO 39.05
- Support Level
- SNGX $2.93
- FOXO $0.43
- Resistance Level
- SNGX $3.35
- FOXO $0.53
- Average True Range (ATR)
- SNGX 0.19
- FOXO 0.06
- MACD
- SNGX -0.01
- FOXO -0.03
- Stochastic Oscillator
- SNGX 37.10
- FOXO 7.76
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About FOXO FOXO Technologies Inc.
FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life.